JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

A novel signature based on twelve programmed cell death patterns to predict the prognosis of lung adenocarcinoma

  • 0Department of Oncology, The First Affiliated Hospital of Nanjing Medical University No. 300 Guangzhou Road, Nanjing, Jiangsu, China.
American Journal of Translational Research +

|

June 17, 2024

|

June 17, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study identifies key programmed cell death (PCD) genes in lung adenocarcinoma (LUAD). A novel gene signature predicts patient outcomes and offers insights into potential therapeutic targets for LUAD.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genetics

Background

  • Programmed cell death (PCD) is crucial in tumor development.
  • The prognostic significance of PCD-related genes (PRGs) in lung adenocarcinoma (LUAD) is not well understood.

Purpose Of The Study

  • To identify and analyze PRGs in LUAD.
  • To develop a prognostic gene signature for LUAD based on PRGs.
  • To explore the therapeutic potential of PRGs in LUAD.

Main Methods

  • Analysis of 1254 genes across twelve PCD patterns.
  • Differential gene expression analysis between LUAD and normal tissues.
  • Univariate and LASSO Cox regression to build a prognostic risk score using seven key genes (DAPK2, DDIT4, E2F2, GAPDH, MET, PIM2, FOXF1).
  • In vitro validation of DDIT4's role in LUAD cell lines.

Main Results

  • Identified 215 differentially expressed PRGs in LUAD.
  • Developed a seven-gene prognostic signature with significant correlation to cancer stage, survival, and immune infiltration.
  • Demonstrated that DDIT4 knockdown enhances apoptosis and reduces proliferation in LUAD cells.

Conclusions

  • A novel PRG-based prognostic signature for LUAD has been established.
  • This signature provides valuable insights into the role of PCD in LUAD progression.
  • The findings suggest potential new therapeutic strategies targeting PRGs in LUAD.

Keywords: